Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
henagliflozin + retagliptin
- Development stage
- Phase 1
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Henagliflozin + retagliptin** is an oral fixed-dose combination therapy for type 2 diabetes mellitus. Henagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that lowers blood glucose by reducing renal glucose reabsorption, promoting urinary glucose excretion. Retagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the incretin system by inhibiting DPP-4, thereby increasing endogenous levels of active glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner. The combination has shown superior glycemic efficacy compared to either agent alone in patients inadequately controlled with metformin, with added benefits on body weight and systolic blood pressure. No severe hypoglycemia was noted in studies[1][5]. Both drugs are being developed by Jiangsu Hengrui Medicine.
- Brand names
- HR20031HR-20031HR 20031
- Other names
- retagliptin + henagliflozinretagliptin phosphate + henagliflozin proline
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)SLC5A1 (Sodium Glucose Cotransporter 1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on henagliflozin + retagliptin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on henagliflozin + retagliptin.